A leader in power and automation technologies and a major MES supplier have signed a memorandum of understanding to collaborate on joint solutions for the life science industries
ABB, the power and automation technology group, and Werum IT Solutions, a pharmaceutical MES supplier, have signed a memorandum of understanding to collaborate on control system solutions for the global pharmaceutical and biotech industries.
These solutions will enable customers to benefit from leading industry expertise for process control systems (DCS) and production management software. Werum is the world’s leading supplier of manufacturing execution systems (MES) and manufacturing IT solutions for the pharmaceutical and biotechnological industries. Its out-of-the-box PAS-X software product is used in approximately 800 pharmaceutical and biotech installations around the world.
Werum’s manufacturing IT solutions help manufacturers to increase efficiency, improve productivity and meet regulatory requirements. The collaboration on joint solutions complements ABB’s control systems offering with the latest MES technology, which is seen as a key component for efficient production workflows in the life science industry.
By bringing together both offerings, ABB and Werum will be able to deliver full-scope engineering and validation solutions according to the GAMP5 guideline and to comply with regulations such as FDA’s 21 CFR Part 11.
‘Our customers will benefit from integrated solutions, paving the way towards the factory of the future,’ said Rüdiger Schlierenkämper, CEO of Werum IT Solutions. ‘Werum, like ABB, is a sector leader. We look forward to working with ABB on joint projects and developing new ideas together.’
‘Werum’s PAS-X MES solution, combined with ABB's control systems, will give our customers in the life science industry a seamless solution for their automation needs,’ said Ilpo Ruohonen, Managing Director of ABB’s Control Technologies business unit. ‘This offering strengthens our portfolio for these rapidly growing industries.’